Selvom der ikke har været foretaget nogle kliniske studier for at evaluere Enbrel behandling af patienter med multipel sclerose, har kliniske studier af andre TNF antagonister hos patienter med multipel sclerose vist forøgelse i sygdoms aktiviteten.
There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see section 4.8) Although no clinical trials have been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other TNF antagonists in patients with multiple sclerosis have shown increases in disease activity.